A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts. METHODS: We enrolled 162 consecutive patients with newly diagnosed myeloma who were 65 years of age or younger and who had at least one sibling. All patients were initially treated with vincristine, doxorubicin, and dexamethasone, followed by melphalan and autologous stem-cell rescue. Patients with an HLA-identical sibling then received nonmyeloablative total-body irradiation and stem cells from the sibling. Patients without an HLA-identical sibling received two consecutive myeloablative doses of melphalan, each of which was followed by autologous stem-cell rescue. The primary end points were overall survival and event-free survival. RESULTS: After a median follow-up of 45 months (range, 21 to 90), the median overall survival and event-free survival were longer in the 80 patients with HLA-identical siblings than in the 82 patients without HLA-identical siblings (80 months vs. 54 months, P=0.01; and 35 months vs. 29 months, P=0.02, respectively). Among patients who completed their assigned treatment protocols, treatment-related mortality did not differ significantly between the double-autologous-transplant group (46 patients) and the autograft-allograft group (58 patients, P=0.09), but disease-related mortality was significantly higher in the double-autologous-transplant group (43% vs. 7%, P<0.001). The cumulative incidence rates of grades II, III, and IV graft-versus-host disease (GVHD) combined and of grade IV GVHD in the autograft-allograft group were 43% and 4%, respectively. Overall, 21 of 58 patients (36%) were in complete remission after a median follow-up of 38 months (range, 10 to 72) after allografting. Of the 46 patients who received two autografts, 25 (54%) died. CONCLUSIONS: Among patients with newly diagnosed myeloma, survival in recipients of a hematopoietic stem-cell autograft followed by a stem-cell allograft from an HLA-identical sibling is superior to that in recipients of tandem stem-cell autografts. (ClinicalTrials.gov number, NCT00415987 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The role of allogeneic and non-myeloablative-allogeneic transplantation in multiple myeloma is controversial with studies showing conflicting results.138–140”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [139]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Szer, J. (1999) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,353
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationGooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Research works printed but not linked: 1
- Sullivan KM, 1991, Semin Hematol, 28, 250
Cited by
Items 101–200 of 503
Rasche, L., Röllig, C., Stuhler, G., Danhof, S., Mielke, S., Grigoleit, G. U., Dissen, L., Schemmel, L.-K., Middeke, J. M., Rücker, V., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.08.024 · Cited by 48
Targeting Immune Checkpoints in Hematologic Malignancies
Alatrash, G., Daver, N. G., & Mittendorf, E. A. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012682 · Cited by 49
“Despite the potential benefit of allo-SCT, the high risk of toxicity has limited its applicability in these patients (Mehta and Singhal, 1998; Bensinger et al., 2001; Bruno et al., 2007; Blade et al., 2010; Bjorkstrand et al., 2011; Roddie and Peggs, 2011).”
BackgroundThe skinny on obesity and plasma cell myeloma: a review of the literature
Carson, K. R., Bates, M. L., & Tomasson, M. H. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.71 · Cited by 48
Costa, L. J., Iacobelli, S., Pasquini, M. C., Modi, R. A., Giaccone, L., Bladé, J., Schönland, S. O., Evangelista, A., Pérez‐Simón, J. A., Hari, P., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0887-4 · Cited by 45
Self-citationArsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial
Qazilbash, M. H., Saliba, R. M., Nieto, Y. L., Parikh, G. C., Pelosini, M., Khan, F. B., Jones, R. B., Hosing, C. M., Mendoza, F. L., Weber, D. M., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.09.019 · Cited by 47
“These approaches include the combination of existing and novel antimyeloma agents in conventional doses [34], tandem ASCT [35,36], maintenance therapy [37], and sequential autologous and allogeneic transplantation [38].”
BackgroundLong-Term Outcome of Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma
Kuruvilla, J. G., Shepherd, J. D., Sutherland, H. J., Nevill, T. J., Nitta, J. Y., Le, A., Forrest, D. L., Hogge, D. E., Lavoie, J. C., Nantel, S. H., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.04.006 · Cited by 47
Shimoni, A., Hardan, I., Ayuk, F. A., Schilling, G., Atanackovic, D., Zeller, W., Yerushalmi, R., Zander, A. R., Kröger, N. M., & Nagler, A. (2010) · Cancer · doi:10.1002/cncr.25228 · Cited by 42
“Matched unrelated donor 23 5 21 (4-58) 4 18 (2-33) F ! M .”
Auner, H. W., Szydlo, R., van Biezen, A., Iacobelli, S., Gahrton, G., Milpied, N. J., Volin, L., Janssen, J. J. W. M., Quoc, S. N., Michallet, M., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.73 · Cited by 43
Htut, M., D’Souza, A., Krishnan, A. Y., Bruno, B., Zhang, M., Fei, M., Díaz, M. Á., Copelan, E. A., Ganguly, S., Hamadani, M., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.10.024 · Cited by 42
“> 24 43 (24) 158 (39) Median follow-up of survivors (range), months 102 (15-171) 99 (7-137)”
BackgroundInfluentialSelf-citationMyelom, O. B. O. D. S. M., Knop, S. T., Engelhardt, M. M., Liebisch, P., Meisner, C., Holler, E., Metzner, B., Peest, D., Kaufmann, M., Bunjes, D. W., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0537-2 · Cited by 42
Caballero‐Velázquez, T., López‐Corral, L., Encinas, C., Castilla‐Llorente, C., Martino, R., Rosiñol, L., Sampol, A., Caballero, D. M., Serrano, D., Heras, I. D. L., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12410 · Cited by 41
“The introduction of non-myeloablative or RIC has reduced morbidity and mortality after allo-SCT, even among elderly patients (Bruno et al, 2007, 2009; Rosi~nol et al, 2008; Rotta et al, 2009).”
BackgroundExtracellular vesicles as potential biomarkers of acute graft-vs-host disease
Lia, G., Brunello, L., Bruno, S., Carpanetto, A., Omedè, P., Festuccia, M. B., Tosti, L., Maffini, E., Giaccone, L., Arpinati, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.277 · Cited by 40
“Overall clinical outcomes were reported in previous reports 27–32 Pneumocystis jirovecii was performed in all patients.”
ResultSelf-citationThe evolution of stem-cell transplantation in multiple myeloma
Mahajan, S., Tandon, N., & Kumar, S. K. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718761776 · Cited by 44
Yin, X., Tang, L., Fan, F., Jiang, Q., Sun, C., & Hu, Y. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0553-8 · Cited by 42
“08) [26, 31, 39, 44, 50, 52, 57, 61] and those receiving allo-SCT as salvage therapy (RR = 0.”
Dhakal, B., Shah, N. D., Kansagra, A. J., Kumar, A., Lonial, S., Garfall, A. L., Cowan, A. J., Poudyal, B. S., Costello, C. L., Gay, F., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.03.019 · Cited by 46
Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms
Ferrero, S., Drandi, D., Mantoan, B., Ghione, P., Omedè, P., & Ladetto, M. (2011) · Hematological Oncology · doi:10.1002/hon.989 · Cited by 41
“Despite these advances, MM remains an incurable disease, with the potential exception of a subset of patients who receive allogeneic stem cell transplants [73,74].”
BackgroundSelf-citationKröger, N. M., Bacher, U., Bader, P., Böttcher, S., Borowitz, M. J., Dreger, P., Khouri, I. F., Olavarría, E., Radich, J. P., Stock, W., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.07.001 · Cited by 40
“The CR rate of alloHSCT after standard MA and after RIC ranged between 27% and 81% [96-102].”
MethodImmunologic approaches for the treatment of multiple myeloma
Rasche, L., Weinhold, N., Morgan, G. J., van Rhee, F., & Davies, F. E. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.03.010 · Cited by 39
“Prospective trials evaluating allo SCT in MM show conflicting results with 3 controlled studies supporting allo SCT versus 4 studies showing no outcome benefit (Table 2) [127-134].”
Experts’ consensus on the definition and management of high risk multiple myeloma
Marcon, C., Simeon, V., Deias, P., Facchin, G., Corso, A., Derudas, D., Montefusco, V., Offidani, M., Petrucci, M. T., Zambello, R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1096852 · Cited by 41
“Among the 5 prospective studies comparing tandem ASCT versus ASCT followed by ALLO at diagnosis, only 2 trials (75, 76) showed prolonged PFS and OS in the ALLO arm.”
BackgroundSelf-citationLadetto, M., Ferrero, S., Drandi, D., Festuccia, M. B., Patriarca, F. F., Mordini, N., Cena, S. E., Benedetto, R. D., Guarona, G., Ferrando, F., et al. (2015) · Leukemia · doi:10.1038/leu.2015.269 · Cited by 36
Self-citationIdentification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma
Anderson, L. D., Cook, D. R., Yamamoto, T. N., Berger, C., Maloney, D. G., & Riddell, S. R. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1009-3 · Cited by 37
“Survival can be prolonged with autologous stem cell transplantation (SCT) and other therapy combinations [1–5], but the disease recurs in almost all patients.”
BackgroundInfluentialRingdén, O. T. H., Shrestha, S., da Silva, G. T., Zhang, M.-J., Dispenzieri, A. A., Remberger, M., Kamble, R., Freytes, C. O., Rp, G., Gibson, J., et al. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.192 · Cited by 36
“Studies not limited to high risk MM patients with autologous followed by allogeneic approach, compared with tandem autologous transplantation, have shown discordant results with an earlier Italian study showing a survival advantage, whereas the recently reported Bone Marrow Transplant Clinical Trials Network 0102 stud…”
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma
Efebera, Y. A., Qureshi, S., Cole, S., Saliba, R. M., Pelosini, M., Patel, R. M., Koca, E., Mendoza, F. L., Wang, M. L., Shah, J. J., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.02.015 · Cited by 39
“included regardless of prognostic factors and disease status after a first auto-HSCT, and the conditioning regimen was 2 Gy total body irradiation [31].”
Giralt, S., Costa, L. J., Maloney, D. G., Krishnan, A. Y., Fei, M., Antin, J. H., Brunstein, C. G., Geller, N. L., Goodman, S. A., Hari, P., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.11.018 · Cited by 37
Reduced-intensity allogeneic transplantation for myeloma: reality bites
Stewart, A. K. (2009) · Blood · doi:10.1182/blood-2008-12-173526 · Cited by 35
“For low-risk patients (absence of t(4;14), normal chromosome 13 and 17, and low beta – 2- microglobulin) treated by conventional chemotherapy followed by tandem AST, 75% are alive at 5 years.”
MethodBlood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007
Ferrara, J. L. M., Anasetti, C., Stadtmauer, E. A., Antin, J. H., Wingard, J. R., Lee, S. J., Levine, J. E., Schultz, K. R., Appelbaum, F. R., Negrin, R. S., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.08.005 · Cited by 36
A simplified technique for delivering total body irradiation (TBI) with improved dose homogeneity
Yao, R., Bernard, D. A., Turian, J. V., Abrams, R. A., Sensakovic, W. F., Fung, H. C. H., & Chu, J. C. H. (2012) · Medical Physics · doi:10.1118/1.3697526 · Cited by 35
Advances in therapy of multiple myeloma
Bladé, J., & Rosiñol, L. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283136984 · Cited by 37
Cooling, L. L. W., Hoffmann, S., Herrst, M., Muck, C., Armelagos, H., & Davenport, R. D. (2009) · Transfusion · doi:10.1111/j.1537-2995.2009.02350.x · Cited by 37
“5 NS Immunoglobulin (mg/dL)¶ IgG (range) 596 (124-4940) 627 (139-4940) 449 (137-4440) NS IgA (range) 47 (6-1380) 67 (6-1380) 37 (6-478) 0.”
InfluentialMaffini, E., Storer, B. E., Sandmaier, B. M., Bruno, B., Sahebi, F., Shizuru, J. A., Chauncey, T. R., Hari, P., Lange, T., Pulsipher, M. A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.200253 · Cited by 35
Self-citationGiarin, M. M., Giaccone, L., Sorasio, R., Sfiligoi, C., Amoroso, B., Cavallo, F., Cipriani, A., Palumbo, A., & Boccadoro, M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.124370 · Cited by 33
Self-citationImmunotherapy for multiple myeloma: Current status and future directions
Ayed, A. O., Chang, L., & Moreb, J. S. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.06.006 · Cited by 32
“Nevertheless, the attractive potential of achieving long-term disease control and cure through the graft-versus-myeloma (GVM) effect of allo-SCT has led to evaluation of the latter in several studies over the past decade (Bjorkstrand et al., 2011; Bruno et al., 2007; Garban et al., 2006; Krishnan et al., 2011; Rosinol…”
BackgroundStemistry: The Control of Stem Cells in Situ Using Chemistry
Davies, S. G., Kennewell, P. D., Russell, A. J., Seden, P. T., Westwood, R., & Wynne, G. M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm500838d · Cited by 39
Allogeneic Stem Cell Transplantation in Multiple Myeloma
Greil, C., Engelhardt, M. M., Finke, J., & Wäsch, R. (2021) · Cancers · doi:10.3390/cancers14010055 · Cited by 33
Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010
Harousseau, J. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.076 · Cited by 36
Inherited thrombotic thrombocytopenic purpura
Galbusera, M., Noris, M., & Remuzzi, G. (2009) · Haematologica · doi:10.3324/haematol.2008.002493 · Cited by 32
Bladé, J., Rosiñol, L., & de Larrea, C. F. (2015) · Blood · doi:10.1182/blood-2014-10-551531 · Cited by 31
“Allo-SCT is a potentially curative approach for patients with MM even in advanced disease (24-28).”
BackgroundPollack, S. M., O'Connor, T. P., Hashash, J. G., & Tabbara, I. A. (2009) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31817f9de1 · Cited by 31
“The Italian study showed benefit from autologous transplant followed by allogeneic transplant as compared with tandem autologous transplant.(78) However, the French study showed no such benefit.”
BackgroundCheema, P. K., Zadeh, S., Kukreti, V., Reece, D. E., Chen, C. I., Trudel, S., & Mikhael, J. R. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.02.013 · Cited by 35
“Also, autologous transplantation followed by dose-reduced allogeneic stem cell transplantation has shown to be safe and increase CR rates [39-41]; however, improvement in EFS and OS compared to tandem autologous transplantation has shown contradictory results in randomized controlled trials [41-43].”
ResultComparison of Twin and Autologous Transplants for Multiple Myeloma
Bashey, A., Pérez, W. S., Zhang, M., Anderson, K. C., Ballen, K. K., Berenson, J. R., To, L. B., Fonseca, R., Freytes, C. O., Gale, R. P., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.07.007 · Cited by 33
“Several prior studies have suggested that allogeneic transplants are associated with a lower relapse risk than autotransplants in myeloma [15-18].”
BackgroundResultBeitinjaneh, A., Saliba, R. M., Bashir, Q., Shah, N. D., Parmar, S., Hosing, C. M., Popat, U., Anderlini, P. N., Dinh, Y. T., Qureshi, S., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.656635 · Cited by 30
Yao, S., Hahn, T., Zhang, Y., Haven, D., Senneka, M. K., Dunford, L. M., Parsons, S. K., Confer, D. L., & McCarthy, P. L. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.06.014 · Cited by 30
“Some evidence shows that autoHCT followed by reduced-intensity alloHCT may be superior to tandem autoHCT [40].”
BackgroundSahebi, F., Garderet, L., Kanate, A. S., Eikema, D.-J., Knelange, N. S., Alvelo, O. F. D., Koç, Y., Blaise, D., Bashir, Q., Moraleda, J. M., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.09.018 · Cited by 29
Brevi, A., Cogrossi, L. L., Lorenzoni, M., Mattorre, B., & Bellone, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845422 · Cited by 32
Lawless, S., Iacobelli, S., Knelange, N. S., Chevallier, P., Blaise, D., Milpied, N. J., Foà, R., Cornelissen, J. J., Lioure, B., Benjamin, R., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.280568 · Cited by 29
“21,22 Although there was a dramatic improvement in NRM with the auto-allo approach compared with allo-fi rst, the NRM remained signi fi cantly higher than with auto-auto and it was only after 5 years of follow-up that an advantage for the auto-allo approach became evident.”
Kim, J., Lee, H., Selimović, Š., Gauvin, R., & Bae, H. (2015) · Drug Safety · doi:10.1007/s40264-015-0284-x · Cited by 34
Is there still a role for stem cell transplantation in multiple myeloma?
Mina, R., & Lonial, S. (2019) · Cancer · doi:10.1002/cncr.32060 · Cited by 32
Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning
Servais, S., Baron, F., & Beguin, Y. P. (2011) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2011.01.019 · Cited by 28
“autologous HSCT followed by an allograft from an HLAidentical sibling (following conditioning with 2 Gy TBI) for all patients with a HLA-identical sibling with a protocol of tandem autologous HSCT for patients without a HLAidentical sibling [37].”
MethodVesole, D. H., Zhang, L., Flomenberg, N., Greipp, P. R., & Lazarus, H. M. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.10.030 · Cited by 29
“Subsequent approaches investigated tandem transplantations earlier in the disease course, involving high-dose therapy with autologous HSCT to provide maximal tumor cytoreduction, followed by NST to eradicate minimal residual disease through the GVM effect [9-15].”
BackgroundResultAglietta, M., Barkholt, L., Schianca, F. C., Caravelli, D., Omazic, B., Minotto, C., Leone, F., Hentschke, P., Bertoldero, G., Capaldi, A., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.11.036 · Cited by 32
“The lower toxicity of the procedure allowed not only to proceed with success with allogeneic transplantation as an up-front treatment in selected malignancies but also to explore the existence of alloreactivity in metastatic solid tumors [18-22].”
BackgroundSelf-citationBjörkstrand, B., & Gahrton, G. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.08.010 · Cited by 28
New Approaches to Management of Multiple Myeloma
Genadieva-Stavric, S., Cavallo, F., & Palumbo, A. P. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0276-6 · Cited by 31
Self-citationBashir, Q., Khan, H. M., Orlowski, R. Z., Amjad, A. I., Shah, N. D., Parmar, S., Wei, W., Rondón, G., Weber, D. M., Wang, M. L., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22273 · Cited by 28
“Two studies that showed superior OS and PFS with allo-HCT were the Italian study and the study by Björkstrand et al, which included all patients irrespective of prognostic factors [18,21].”
ResultOostvogels, R., Kneppers, E., Minnema, M. C., Doorn, R., Franssen, L. E., Aarts‐Riemens, T., Emmelot, M. E., Spierings, E., Slaper‐Cortenbach, I., Westinga, K., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.250 · Cited by 27
Garderet, L., D’Souza, A., Jacobs, P., van Biezen, A., Schönland, S. O., Kröger, N. M., Morris, C., & Hari, P. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.03.009 · Cited by 30
“The 2 procedures are usually carried out within 3 to 6 months in the absence of any intervening progression of MM [36,37].”
BackgroundGaballa, S. R., Saliba, R. M., Srour, S. A., Lu, G. G., Brammer, J. E., Shah, N. D., Bashir, Q., Patel, K. K., Bock, F. M., Parmar, S., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24487 · Cited by 29
“Allogeneic HCT, although controversial, is being explored in clinical trials [27,28].”
BackgroundFadilah, S. A. W. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1313-0 · Cited by 28
“This tandem transplant approach allows prolonged survival and long-term disease control in patients with reduced tumor burden at the time of allografting [95] (Table 2).”
BackgroundResultExtended SSD VMAT treatment for total body irradiation
Pierce, G., Balogh, A., Frederick, R., Gordon, D., Yarschenko, A., & Hudson, A. (2018) · Journal of Applied Clinical Medical Physics · doi:10.1002/acm2.12519 · Cited by 26
Smith, E. L., Devlin, S. M., Kosuri, S., Orlando, E. H., Landau, H. J., Lesokhin, A. M., Chung, D. J., Hassoun, H., Lendvai, N. K., Landgren, O., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.08.025 · Cited by 25
Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center
Bensinger, W., Rotta, M., Storer, B. E., Chauncey, T. R., Holmberg, L., Becker, P. S., Sandmaier, B. M., Storb, R. F., & Maloney, D. G. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.1 · Cited by 27
Self-citationImmunotherapy for Multiple Myeloma
Tamura, H., Ishibashi, M., Sunakawa, M., & Inokuchi, K. (2019) · Cancers · doi:10.3390/cancers11122009 · Cited by 27
“Two studies showed longer progression-free survival (PFS) and OS times in MM patients treated with nonmyeloablative allo-SCT after auto-SCT compared with those treated with tandem auto-SCT [10,11], indicating that allo-SCT could be effective in a limited subset of patients with a small amount of residual myeloma cells…”
BackgroundBest Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area
Bianchi, G., Richardson, P. G. G., & Anderson, K. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7900 · Cited by 26
Giaccone, L., Evangelista, A., Patriarca, F. F., Sorasio, R., Pini, M., Carnevale‐Schianca, F., Festuccia, M. B., Brunello, L., Zallio, F., Maffini, E., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.09.017 · Cited by 25
“METHODS Study Population and Treatment Assignment Study design and clinical outcomes were previously published [1].”
InfluentialSelf-citationManagement of multiple myeloma: The changing landscape
Reece, D. E. (2007) · Blood Reviews · doi:10.1016/j.blre.2007.07.001 · Cited by 26
Use of biological assignment in hematopoietic stem cell transplantation clinical trials
Logan, B. R., Leifer, E., Bredeson, C., Horowitz, M. M., Ewell, M., Carter, S., & Geller, N. L. (2008) · Clinical Trials · doi:10.1177/1740774508098326 · Cited by 24
Bashir, Q., Khan, H. M., Thall, P. F., Liu, P., Shah, N. D., Kebriaei, P., Parmar, S., Oran, B., Ciurea, S. O., Nieto, Y. L., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.07.008 · Cited by 26
“Overall, 2 randomized trials have shown that auto-HCT followed by RIC allo-HCT leads to superior PFS andOS [35,36].”
BackgroundValdimarsdottir, H. B., Figueiro, M. G., Holden, W. L., Lutgendorf, S. K., Wu, L. M., Ancoli‐Israel, S., Chen, J., Hoffman-Peterson, A., Granski, J., Prescott, N., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1690 · Cited by 24
“923], and on the third day of engraftment [F(1,11) = 0.”
BackgroundStem-cell transplantation in multiple myeloma: how far have we come?
Soekojo, C. Y., & Kumar, S. K. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719888111 · Cited by 27
Role of Stem Cell Transplantation
Harousseau, J. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.001 · Cited by 30
Kröger, N. M. (2007) · Leukemia · doi:10.1038/sj.leu.2404775 · Cited by 23
Levenga, H., Schaap, N. P., Maas, F., Esendam, B., Fredrix, H., Greupink-Draaisma, A., de Witte, T., Dolstra, H., & Raymakers, R. A. P. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.10.006 · Cited by 29
“[2] showed a superior overall survival (OS) for autologous SCT followed by allogeneic RIC-SCT.”
BackgroundResultCaltagirone, S., Ruggeri, M., Aschero, S., Gilestro, M., Oddolo, D., Gay, F., Bringhen, S., Musolino, C., Baldini, L., Musto, P., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.103853 · Cited by 24
Self-citationLudwig, H., Strasser‐Weippl, K., Schreder, M., & Zojer, N. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm296 · Cited by 24
Changing paradigms in the treatment of multiple myeloma
Bladé, J., & Rosiñol, L. (2009) · Haematologica · doi:10.3324/haematol.2008.002766 · Cited by 23
Green, D. J., Maloney, D. G., Storer, B. E., Sandmaier, B. M., Holmberg, L. A., Becker, P. S., Fang, M., Martin, P. J., Georges, G. E., Bouvier, M. E., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010686 · Cited by 23
Self-citationRaje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Mahtouk, K., Hose, D., Vos, J. D., Moreaux, J., Jourdan, M., Rossi, J. F., Reme, T. X., Goldschmidt, H., & Klein, B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1758 · Cited by 23
Stem cell transplantation for multiple myeloma
Kumar, S. K. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328324bc04 · Cited by 25
Hayden, P. J., Mitsiades, C. S., Anderson, K. C., & Richardson, P. G. G. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282f0e948 · Cited by 25
Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Pant, S., & Copelan, E. A. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.05.002 · Cited by 22
Melphalan: old and new uses of a still master drug for multiple myeloma
Musto, P., & D’Auria, F. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.9.1467 · Cited by 21
“In the transplant setting, intensified induction and post-transplantation consolidation/maintenance therapies, optimization of tandem ASCT/RICT procedures and, possibly, the anticipation of these treatments, could improve, particularly in high risk patients, the results of the present HDM-based procedures [143,148-150…”
BackgroundResultPassera, R., Pollichieni, S., Brunello, L., Patriarca, F. F., Bonifazi, F., Montefusco, V., Falda, M., Montanari, M., Guidi, S., Giaccone, L., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.03.012 · Cited by 21
“The most recently published prospective studies were designed before new drugs with potent antimyeloma activity became readily available [11,12], enrolled newly diagnosed patients, used reduced-intensity or nonmyeloablative conditionings and donors were most frequently HLA-identical siblings [13-23].”
BackgroundSelf-citationGill, S. I., & Porter, D. L. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-121411-103452 · Cited by 21
Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?
Gahrton, G., Iacobelli, S., Garderet, L., Yakoub‐Agha, I., & Schönland, S. O. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072180 · Cited by 21
A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma
Bensinger, W., Green, D. J., Burwick, N. R., & Becker, P. S. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.219 · Cited by 21
Treatment of multiple myeloma in patients with Gaucher disease
Machaczka, M., Lerner, R., Klimkowska, M., & Hägglund, H. (2009) · American Journal of Hematology · doi:10.1002/ajh.21492 · Cited by 20
Michallet, M., Sobh, M., Cheikh, J. E., Morisset, S., Sîrvent, A., Reman, O., Cornillon, J., Tabrizi, R., Milpied, N. J., Harousseau, J., et al. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.08.003 · Cited by 20
“[32], RIC allogeneic HSCT was proposed to MM patients with an HLA-identical sibling donor using a tandem approach versus a double-autologous transplantation [32].”
Cellular immunotherapy in multiple myeloma: Lessons from preclinical models
Binsfeld, M., Fostier, K., Muller, J., Baron, F., Schots, R., Beguin, Y. P., Heusschen, R., & Caers, J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.08.001 · Cited by 20
“Another study showed, in contrast, an overall benefit for auto-allo-SCT arm in newly diagnosedMMwith superior survival [73].”
Ahmad, I., LeBlanc, R., Cohen, S., Lachance, S., Kiss, T. L., Sauvageau, G., Roy, D.-C., Busque, L., Delisle, J., Bambace, N. M., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.319 · Cited by 21
Franssen, L. E., Raymakers, R. A. P., Buijs, A., Schmitz, M. F., van Dorp, S., Mutis, T., Lokhorst, H. M., & van de Donk, N. W. C. J. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12758 · Cited by 20
Paviglianiti, A., Xavier, E., Ruggeri, A., Céballos, P., Deconinck, É., Cornelissen, J. J., Nguyen‐Quoc, S., Maillard, N., Sanz, G. F., Rohrlich, P., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.138917 · Cited by 21
“Different studies comparing tandem ASCT to alloSCT/RIC have given discordant results, with some of them failing to demonstrate the benefit of alloSCT/RIC.(10,14,15) There is, therefore, a general hesitancy in recommending up-front alloSCT.”
ResultEvolving Role of Daratumumab: From Backbencher to Frontline Agent
Jain, A., & Ramasamy, K. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.03.010 · Cited by 20
Carnevale‐Schianca, F., Caravelli, D., Gallo, S., Becco, P., Paruzzo, L., Poletto, S., Polo, A., Mangioni, M., Salierno, M., Berger, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061173 · Cited by 20
Self-citationMosebach, J., Shah, S., Delorme, S., Hielscher, T., Goldschmidt, H., Schlemmer, H., Schönland, S. O., Hegenbart, U., & Hillengaß, J. (2017) · Haematologica · doi:10.3324/haematol.2017.176073 · Cited by 20
Kawamura, K., Tsukada, N., Kanda, Y., Ikeda, T., Yoshida, A., Ueda, Y., Ishida, T., Suzuki, K., & Murakami, H. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.03.012 · Cited by 21
Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs
Festuccia, M. B., Martino, M. V., Ferrando, F., Messina, G., Moscato, T., Fedele, R., Boccadoro, M., Giaccone, L., & Bruno, B. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1036735 · Cited by 20
“An Italian randomized trial showed improvement in PFS and OS in the auto/allo-SCT group [8,25].”
Self-citationWhat happens to regulatory T cells in multiple myeloma
Chen, H., Wang, X., Wang, Y., & Chang, X. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01765-8 · Cited by 23
“It has been reported that the relapse rate of MM decreases after Allo-HSCT treatment [144, 145].”
BackgroundAvigan, D., Hari, P., Battiwalla, M., Bishop, M. R., Giralt, S., Hardy, N. M., Kröger, N. M., Wayne, A. S., & Hsu, K. C. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.08.011 · Cited by 19
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts
Patriarca, F. F., Petrucci, M. T., Bringhen, S., Baldini, L., Caravita, T., Corradini, P., Corso, A., Raimondo, F. D., Falcone, A. P., Ferrara, F., et al. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01179.x · Cited by 21
“Final results from two randomised prospective trials (53, 54) in newly diagnosed patients, comparing a double ASCT with a single Considerations in the treatment of multiple myeloma Patriarca et al.”
BackgroundSelf-citationAllogeneic Hematopoietic Cell Transplantation in the Outpatient Setting
Granot, N., Storer, B. E., Cooper, J. P., Flowers, M. E. D., Sandmaier, B. M., & Storb, R. F. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.025 · Cited by 19
Self-citation
Metadata
- Authors
- Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., Bringhen, S., Massaia, M., Aglietta, M., Levis, A., Gallamini, A., Fanin, R., Palumbo, A., Storb, R., Ciccone, G., & Boccadoro, M.
- Affiliations
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- University of Udine (IT)
- Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT)
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo (IT)
- Candiolo Cancer Institute (IT)
- University of Washington (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-03-15
- Volume
- 356
- Issue
- 11
- Pages
- 1110-1120
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2010766702
- Semantic Scholar
- 67383c7f6bdb3318b2667d1aad826b28d4117193
- Cited by
- 501
- References
- 35
- Citations by year
- 2025: 3 · 2024: 8 · 2023: 11 · 2022: 10 · 2021: 14 · 2020: 16 · 2019: 13 · 2018: 16 · 2017: 26 · 2016: 22 · 2015: 34 · 2014: 23 · 2013: 43 · 2012: 33
- FWCI
- 40.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- National Cancer Institute (CA 78902, P01CA078902)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, allogeneic stem cell transplantation, autologous stem cell transplantation, matched sibling donor, graft-versus-host disease, overall survival, event-free survival, complete remission, non-relapse mortality, newly diagnosed multiple myeloma
- MeSH terms
- Adult, Aged, Female, Follow-Up Studies, Graft vs Host Disease, Histocompatibility Testing, Humans, Male, Middle Aged, Multiple Myeloma, Transplantation, Autologous, Transplantation, Homologous, Multivariate Analysis, Survival Analysis, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Siblings
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.